People · Operator
Named in public records as an officer, director or promoter · active 2018–2021 · Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nurix Therapeutics, Inc. | — | Pharma | Series D+ | $144.7M | $4.2B | 2020 |
| Iconic Therapeutics Inc | — | Biotechnology | Series C | $79.0M | $533.7M | 2018 |
| IMV Inc. | — | Biotechnology | Seed | $4.3M | $14.8M | 2021 |
Julia Gregory at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Julia Gregory on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| LEON CHEN | 1 | 15 |
| Todd Foley | 1 | 12 |
| David Goeddel | 1 | 10 |
| Bruce Cohen | 1 | 7 |
| Bruce Robertson | 1 | 7 |
| Peter Hirth | 1 | 7 |
| Michael Bailey | 1 | 6 |
| William Greene | 1 | 6 |
| Johan Kordel | 1 | 4 |
| Andrew Hall | 1 | 4 |
| Kyle Kuvalanka | 1 | 3 |
| Robert Tjian | 1 | 3 |
| Markus Warmuth | 1 | 3 |
| Julia P. Gregory | 1 | 3 |
| Shermaine Tilley | 1 | 3 |
| Michael Kalos | 1 | 2 |
| Mark Goldsmith | 1 | 2 |
| Arthur T Sands | 1 | 2 |
| Jeff Tong | 1 | 2 |
| Pierre Labbe | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.